PT  - JOURNAL ARTICLE
AU  - W Frank
AU  - R Moritz
AU  - B Becke
AU  - R Pauli
TI  - Low dose cabergoline induced interstitial pneumonitis
AID  - 10.1034/j.1399-3003.1999.14d40.x
DP  - 1999 Oct 01
TA  - European Respiratory Journal
PG  - 968--970
VI  - 14
IP  - 4
4099  - http://erj.ersjournals.com/content/14/4/968.short
4100  - http://erj.ersjournals.com/content/14/4/968.full
SO  - Eur Respir J1999 Oct 01; 14
AB  - Certain dopaminergic anti-Parkinson drugs (ergolines) have repeatedly been identified as a cause of pleuropulmonary disease with a focus on serosal cell damage. Recently, a pathogenetic link between ergolines and prior asbestos exposure was suggested, as regards the development of pleural pathology. This report describes a patient with idiopathic Parkinson's disease, who was on a multiple drug regimen including low dose cabergoline. The patient developed a febrile illness with widespread bilateral lung infiltrations nonresponsive to beta-lactam and macrolide antibiotics. Bronchoalveolar lavage and transbronchial lung biopsy showed a "hypersensitivity-like" interstitial lung disease, which cleared almost completely within 2 months after simple drug withdrawal. Circumstantial evidence suggests a so far undescribed adverse lung reaction to cabergoline, devoid of the more usual pleural changes.